MOVING FORWARD

ABOUT US

We are a pharmaceutical company specialized in high-quality oncology products in the Middle East. Actero is the result of the joint venture between Actoverco (the Iranian leading pharmaceutical company) and a renowned multinational company currently present in 120 countries.
We are the combination of world-class quality standards and local production capabilities.

WE ARE ACTERO.

WE APPLY

HIGH-TECHNOLOGY

State-of-the-art technology and international know-how are the building blocks to ensure safe and effective oncology products.

WE ARE

RESPONSIBLE

Our responsibilities go beyond the supply of oncology products. We feel committed to physicians and patients, so that together we can beat cancer.

WE ARE

HARD WORK

We believe there are no shortcuts to excellence. Hard work and perseverance are the only way to achieve quality.

WE ARE

TRUST

We think trust is the foundation of any relationship. We will put our best effort to gain the trust of all of our stakeholders.

MANUFACTURING EXCELLENCE 

We place international quality standards at the heart of our manufacturing process. Our state-of-the-art facility is equipped with both injectable and solid dosage production lines under strict GMP standards. OEL 4 criteria have been respected during all phases of design, execution and operation of the plant. Our manufacturing facility is located at Baharestan industrial zone with a building area of 7000sqm, and the capacity of 1.5 million vials, 250 million tablets and 6 million capsules.

This manufacturing facility will provide oncology products for the local market, as well as export markets.

WE ARE ACTERO.

QUALITY STANDARDS

Quality is the hallmark of all activities performed at Actero. All our operations, from product development to the manufacturing and commercial release are consistent and compliant with global regulatory requirements.

BUSINESS DEVELOPMENT

The business development team at Actero has in depth knowledge of the oncology field and maintains a close collaboration with our international partners. Their goal is to add the latest efficacy-proven molecules to our portfolio.